IMAB

I-MAB

IMAB

Market cap $334M

Overview Fund Activity

4.09 USD

+0.19

4.87%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

4.00

-0.09

2.2%

1 day

4.87%

5 days

-7.67%

1 month

6.23%

3 months

58.53%

6 months

401.84%

Year to date

351.43%

1 year

293.27%

5 years

-89.65%

10 years

-67.28%

About: I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).

Employees: 32

Healthcare Biotechnology

0

Funds holding %

of 7,462 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

207% more capital invested

Capital invested by funds: $7.41M [Q1] → $22.7M (+$15.3M) [Q2]

25% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 8

7% more funds holding

Funds holding: 29 [Q1] → 31 (+2) [Q2]

6.67% more ownership

Funds ownership: 4.83% [Q1] → 11.51% (+6.67%) [Q2]

38% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 8

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$6

47% upside

Avg. target

$6.75

65% upside

High target

$7

71% upside

4 analyst ratings

4 positive

100%

0 neutral

0%

0 negative

0%

BTIG Justin Zelin	$7	Buy Reiterated	10 Sep 2025
Needham Gil Blum	$6	Buy Reiterated	8 Sep 2025
HC Wainwright & Co. Andres Y. Maldonado	$7	Buy Reiterated	21 Aug 2025
HC Wainwright & Co. Andres Maldonado	$7	Buy Reiterated	9 Jul 2025

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about IMAB published over the past 30 days

I-Mab: Sudden Pivot To Gastric Cancer Med Still Underappreciated By Market

I-Mab has pivoted to focus on givastomig for gastric cancer, after divesting its original China portfolio and revamping leadership. Givastomig shows superior early efficacy versus rivals, with promising ORR and safety, but key Phase 1b/2 data in Q1 2026 will be critical. Despite past setbacks, I-Mab's cash runway and undervalued market cap position it for potential upside if upcoming data is positive.

I-Mab: Sudden Pivot To Gastric Cancer Med Still Underappreciated By Market

Zacks Investment Research

Are You Looking for a Top Momentum Pick? Why I-Mab Sponsored ADR (IMAB) is a Great Choice

Does I-Mab Sponsored ADR (IMAB) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why I-Mab Sponsored ADR (IMAB) is a Great Choice

I-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development Committee

ROCKVILLE, Md., Aug. 25, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced the appointment of independent directors, Dr. Robert Lenz and Ms. Xin Liu, to its Board of Directors (the Board), effective as of August 22, 2025 and reiterated the appointment of independent director Dr. Sean Cao to the Board as of May 28, 2025. The Company also announced Lielie Zhang will be stepping down from the Board, effective as of August 20, 2025, with gratitude for his dedicated service. In addition, I-Mab announced the formation of a Research and Development Committee of the Board of Directors (the R&D Committee), to be chaired by Dr. Robert Lenz, with Dr. Sean Cao and Dr. Sean Fu, Chief Executive Officer of I-Mab, as members. I-Mab will also expand its Scientific Advisory Board (SAB) with the appointment of Dr. Ken Takeshita.

I-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development Committee

I-Mab to Participate in September Investor Conferences

ROCKVILLE, Md., Aug. 21, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab's management team will participate in the following upcoming investor conferences in September, 2025:

I-Mab to Participate in September Investor Conferences

Everest Medicines Expands Strategic Investment in I-MAB

- Everest will invest US$30.9 million (equivalent to approximately HK$242.6 million) in cash in I-Mab. Inclusive of I-MAB shares already held by Everest, the pro forma ownership will be 16.1%.

Everest Medicines Expands Strategic Investment in I-MAB

I-Mab Announces Pricing of $65 Million Underwritten Offering of American Depositary Shares

ROCKVILLE, Md., Aug. 01, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced the pricing of an underwritten offering in the United States of 33,333,334 American Depositary Shares (ADSs) representing 76,666,668 ordinary shares at an offering price of $1.95 per ADS, for total gross proceeds of approximately $65 million. All of the ADSs to be sold in the offering will be offered by I-Mab. The offering is expected to close on August 5, 2025, subject to customary closing conditions.

I-Mab Announces Pricing of $65 Million Underwritten Offering of American Depositary Shares

I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health

ROCKVILLE, Md., July 17, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that it entered into a definitive agreement to acquire 100% ownership of Bridge Health Biotech Co., Ltd. (Bridge Health). The transaction provides I-Mab with the rights to bispecific and multi-specific applications (including bispecific and multi-specific antibodies and antibody drug conjugates (ADCs)), based on the Claudin 18.2 (CLDN18.2) parental antibody used in the Company's CLDN18.2 x 4-1BB bispecific antibody, givastomig.

I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health

I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025

Data show confirmed ORR of 83% (10/12) at doses selected for ongoing expansion study Median follow-up of 9.0 months as of the updated data cutoff Responses observed in patients with low PD-L1 and/or CLDN18.2 expression Company to host investor event on Tuesday, July 8 th ROCKVILLE, Md., July 02, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced the presentation of positive Phase 1b combination data for givastomig, in combination with nivolumab and mFOLFOX6, at the European Society for Medical Oncology Gastrointestinal Cancers Congress 2025 (ESMO GI 2025) in Barcelona (abstract #388MO).

I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025

I-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research

Monotherapy efficacy and safety profile provided backbone for clinical development strategy in 1L combination with nivolumab plus chemotherapy

I-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research

I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025

71% objective response rate (ORR) (12/17) per RECIST v1.1, with a favorable safety profile 83% ORR (10/12) in patients across doses selected for ongoing dose expansion study Responses observed in patients with low PD-L1 and/or CLDN18.2 expression Updated results to be presented at ESMO GI on July 2 nd Company to host investor event on July 8 th ROCKVILLE, Md., June 26, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced publication of ESMO Gastrointestinal Cancers Congress 2025 (ESMO GI 2025) abstract #388MO related to positive data from a Phase 1b study evaluating givastomig in combination with nivolumab and mFOLFOX6 chemotherapy for metastatic gastric cancers.

I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025

See News Rankings

Charts implemented using Lightweight Charts™